Last edition
News about "Leqembi "
China Grants Priority Review to Leqembi Subcutaneous BLA
The Priority Review and Approval Procedure has been implemented by the NMPA with the aim of accelerating research, development and launch of new medicines that have significant clinical value. Under this procedure, the assessment period is expected to be shortened.
Leqembi | 11/02/2026 | By News Bureau | 107
China Adds Leqembi to Innovative Drug Insurance List
BioArctic’s partner Eisai said Leqembi has been added to China’s new Commercial Insurance Innovative Drug List, a move by the NHSA that broadens access to the Alzheimer’s therapy for patients in the early stages of the disease.
Leqembi | 09/12/2025 | By Akanki | 216
Leqembi sBLA for Alzheimers IV Maintenance Moves Forward with FDA
Eisai has submitted a supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb intravenous (IV) maintenance dosing to the US Food and Drug Administration (FDA).
Leqembi | 01/04/2024 | By Manvi | 648
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy